How Characterization Analytics Smooths The Path To IND

Early analytical decisions can quietly determine whether a program moves smoothly toward commercialization or stalls under avoidable risk. In this Q&A, experts walk through two real-world case studies showing how investing in fit-for-purpose analytical strategies early—from IND-enabling work through commercial manufacturing—can prevent costly surprises later. The conversation moves beyond theory to address practical questions, including which analytical capabilities are essential in-house versus at a CDMO, where scale-up most often breaks down, and how teams can anticipate issues before timelines are threatened. See how experienced partners approach late-stage challenges such as aggregation, degradation, and comparability during tech transfer, translating complex data into clear, actionable insights that help programs regain momentum when uncertainty emerges.
Access the full piece to better understand how robust analytics support smarter, lower-risk development decisions.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.